Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.
Haruka TsuchiyaKeishi FujioPublished in: International journal of molecular sciences (2021)
Rheumatoid arthritis (RA) is an autoimmune disease characterized by destructive synovitis. It is significantly associated with disability, impaired quality of life, and premature mortality. Recently, the development of biological agents (including tumor necrosis factor-α and interleukin-6 receptor inhibitors) and Janus kinase inhibitors have advanced the treatment of RA; however, it is still difficult to predict which drug will be effective for each patient. To break away from the current therapeutic approaches that could be described as a "lottery," there is an urgent need to establish biomarkers that stratify patients in terms of expected therapeutic responsiveness. This review deals with recent progress from multi-faceted analyses of the synovial tissue in RA, which is now bringing new insights into diverse features at both the cellular and molecular levels and their potential links with particular clinical phenotypes.
Keyphrases
- rheumatoid arthritis
- disease activity
- end stage renal disease
- current status
- ankylosing spondylitis
- multiple sclerosis
- interstitial lung disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- case report
- peritoneal dialysis
- cardiovascular events
- drug induced
- adverse drug
- systemic lupus erythematosus
- risk assessment
- cardiovascular disease
- coronary artery disease
- single molecule
- combination therapy
- human health
- idiopathic pulmonary fibrosis